Boston Scientific (NYSE:BSX) said today it inked a $275 million deal to acquire women’s health-focused NVision Medical, which produces an FDA-cleared device designed to collect cells from fallopian tubes as an early diagnosis of ovarian cancer. In the deal, Boston Scientific will pay $150 million up front with an additional $125 million in possible milestone payments […]
NVision
Women’s health focused NVision Medical raises $12m in Series B
Stealthy NVision Medical has raised $12 million in Series B financing, with funds slated to support product development, clinical studies and regulatory submissions to for its micro-catheter technology. NVision’s microcatheter technology is designed to allow access to the fallopian tubes without the need for incisions or general anesthesia in hopes of providing “an array of clinical indications […]
Stealthy early-stage NVision Medical raises $6.5m
Stealthy NVision Medical raised $6.5 million in a new round of equity financing to support its ovarian cancer diagnostic device, according to an SEC filing. NVision is an early-stage medical device company focused on women’s health, specifically creating in-office diagnostics for ovarian cancer and fallopian tube blockages, according to a 2014 interview with MedCity News. […]
Cardiac Dimensions taps ex-AccessClosure chief Casciaro for CEO | Personnel Moves
Cardiac Dimensions said this week that it tapped the former chief of AccessClosure, Gregory Casciaro, to be its new president & CEO. Casciaro led AccessClosure until its May 2014 acquisition by Cardinal Health (NYSE:CAH) for $320 million. His résumé includes stints as the chief executive at drug-eluting stent maker Xtent, Orquest (acquired JNJ’s DePuy Acromed in 2003) […]
